AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
MoonLake Immunotherapeutics (NASDAQ:MLTX)
19.21 USD
+0.020 0.104%Sponsored Reports
Loading...
| Previous Close (in USD) | 19.19 |
|---|---|
| Change | +0.020 0.104% |
| 52 W H/L (in USD) | 64.980/24.310 |
| EBITDA (in USD) | -60.979M |
| PE Ratio | -- |
| Volume | 774519 |
| Diluted Eps TTM | -0.73 |
| Total Assets (in USD) | 526.54M |
|---|---|
| Total Liabilities (in USD) | 13.049M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 451.169M |
| Market Cap (in USD) | 2,621.871 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Employees: 50
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Jorge Santos da Silva | Co-Founder, CEO & Director | 1978 |
| 2. | Dr. Kristian Reich | Co-Founder & Chief Scientific Officer | 1966 |
| 3. | Mr. Matthias Bodenstedt | Chief Financial Officer | 1988 |
| 4. | Mr. Oliver Daltrop | Chief Technical Officer | NA |
| 5. | Ms. Nuala Brennan | Chief Clinical Devel. Officer | NA |
| 6. | Nicolas Mosimann | General Counsel | NA |
| 7. | Luciana Marques | Director of HR, People & Culture | NA |
| 8. | Ms. Nuala Brennan | Chief Clinical Development Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|
| Income Before Tax | -43.985M | -64.47M | -4.543M | -0.091M |
| Minority Interest | 6.982M | -14.533M | - | - |
| Net Income | -36.007M | -64.506M | -4.543M | -0.091M |
| Selling General Administrative | 22.321M | 23.012M | 4.57M | - |
| Gross Profit | -0.013M | -0.012M | -0.005M | - |
| Reconciled Depreciation | 0.013M | 0.012M | - | - |
| Ebit | -54.123M | -65.061M | -4.57M | - |
| Ebitda | -54.11M | -65.049M | -4.57M | -0.106M |
| Depreciation And Amortization | 0.013M | 0.012M | 0.005M | - |
| Operating Income | -54.123M | -65.061M | -4.57M | -0.106M |
| Other Operating Expenses | 54.123M | 65.061M | 4.57M | 0.106M |
| Interest Expense | - | 0.592M | 0M | - |
| Tax Provision | 0.061M | 0.036M | - | - |
| Interest Income | - | - | - | - |
| Net Interest Income | - | - | - | - |
| Income Tax Expense | 0.094M | 0.036M | 0.006M | - |
| Total Revenue | 0M | 0M | - | - |
| Total Operating Expenses | 54.11M | 65.061M | 4.57M | 0.106M |
| Cost Of Revenue | 0.013M | 0.012M | 0.005M | - |
| Total Other Income Expense Net | 10.138M | 0.592M | 0.028M | 0.015M |
| Net Income From Continuing Ops | -52.66M | -50.098M | -4.543M | - |
| Net Income Applicable To Common Shares | - | -49.973M | -4.543M | - |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|
| Total Assets | 526.54M | 76.843M | 9.682M | 116.634M |
| Intangible Assets | - | - | - | - |
| Other Current Assets | 2.102M | 4.179M | 0.127M | 0.283M |
| Total Liab | 13.049M | 8.077M | 21.327M | 4.15M |
| Total Stockholder Equity | 495.676M | 48.898M | -11.645M | 112.484M |
| Other Current Liab | 8.4M | 7.257M | 4.659M | 0.067M |
| Common Stock | 0.006M | 0.005M | 0.039M | 115M |
| Capital Stock | 0.006M | 0.005M | 0.111M | - |
| Retained Earnings | -116.657M | -80.65M | -53.644M | -2.517M |
| Good Will | - | - | - | - |
| Other Assets | 0M | - | - | - |
| Cash | 451.169M | 39.506M | 8.039M | 1.336M |
| Cash And Equivalents | - | - | - | - |
| Total Current Liabilities | 9.966M | 7.665M | 21.088M | 0.125M |
| Current Deferred Revenue | -0.185M | - | - | - |
| Net Debt | -447.471M | -39.223M | 6.961M | -1.278M |
| Short Term Debt | 1.198M | 0.154M | 15M | 0.058M |
| Short Long Term Debt | - | - | 15M | - |
| Short Long Term Debt Total | 3.698M | 0.283M | 15M | 0.058M |
| Other Stockholder Equity | 609.969M | 129.192M | 42.056M | - |
| Property Plant Equipment | - | 0.049M | 0.046M | - |
| Total Current Assets | 514.167M | 76.511M | 9.637M | 1.619M |
| Long Term Investments | - | - | - | - |
| Short Term Investments | 59.839M | 32.609M | - | - |
| Net Receivables | 1.057M | 0.217M | 0.149M | - |
| Long Term Debt | - | - | - | - |
| Inventory | - | - | 1.322M | - |
| Accounts Payable | 0.553M | 0.255M | 1.428M | - |
| Accumulated Other Comprehensive Income | 2.358M | 0.351M | -0.168M | - |
| Non Currrent Assets Other | 8.423M | 0.283M | -115.043M | - |
| Non Current Assets Total | 12.373M | 0.332M | 0.046M | 115.015M |
| Capital Lease Obligations | 3.806M | 0.283M | - | - |
| Long Term Debt Total | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|
| Investments | -132.15M | -32.325M | - | - |
| Total Cashflows From Investing Activities | - | -32.341M | -0.061M | - |
| Total Cash From Financing Activities | 479.702M | 119.693M | 43.263M | 116.653M |
| Net Income | -36.007M | -64.506M | -53.644M | -0.091M |
| Change In Cash | 411.664M | 31.467M | 6.703M | 1.336M |
| Begin Period Cash Flow | 39.506M | 8.039M | 1.336M | - |
| End Period Cash Flow | 451.169M | 39.506M | 8.039M | 1.336M |
| Total Cash From Operating Activities | -42.778M | -55.894M | -35.175M | -0.317M |
| Depreciation | 0.013M | 0.012M | 0.005M | - |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | 0.052M | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | - | 0.004M | -0.006M | - |
| Other Cashflows From Financing Activities | -2.753M | 134.689M | 0.052M | -0.347M |
| Capital Expenditures | 0.285M | 0.016M | 0.051M | 0M |
| Change In Working Capital | -6.218M | -1.427M | 4.484M | -0.216M |
| Other Non Cash Items | 0.3M | 0.372M | 12.569M | -0.01M |
| Free Cash Flow | -43.063M | -55.91M | -35.226M | -0.317M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | T. Rowe Price Health Sciences | 2 years ago | 1050793 |
| 2. | Polar Capital Healthcare Opports Inc | 2 years ago | 608772 |
| 3. | Federated Hermes Kaufmann R | 2 years ago | 555000 |
| 4. | Federated Hermes Kaufmann Growth | 2 years ago | 555000 |
| 5. | US Small-Cap Growth II Equity Comp | 2 years ago | 522634 |
| 6. | T. Rowe Price New Horizons | 2 years ago | 522634 |
| 7. | Fidelity Contrafund | 2 years ago | 494777 |
| 8. | Alger Small Cap Focus I | 2 years ago | 483565 |
| 9. | Alger Small Cap Focus Composite | 2 years ago | 483565 |
| 10. | Federated Hermes Kaufmann Small Cap Grow | 2 years ago | 471276 |
| 11. | Federated Hermes Kaufmann Small Cap A | 2 years ago | 471276 |
| 12. | MEDICAL BioHealth EUR Acc | 2 years ago | 435619 |
| 13. | T. Rowe Price Small-Cap Stock | 2 years ago | 421422 |
| 14. | T. Rowe Price US Small-Cap Core Equity | 2 years ago | 421422 |
| 15. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 416034 |
| 16. | Westfield Capital Mgt Co Sm-Cap Gr Eq | 2 years ago | 400519 |
| 17. | Harbor Small Cap Growth Instl | 2 years ago | 400519 |
| 18. | Fidelity Blue Chip Growth | 2 years ago | 396524 |
| 19. | APO Medical Opportunities R | 2 years ago | 338071 |
| 20. | Fidelity Select Biotechnology | 2 years ago | 309841 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bvf Inc | 2 years ago | 21751284 |
| 2. | AllianceBernstein L.P. | 2 years ago | 955507 |
| 3. | Cormorant Asset Management, LLC | 2 years ago | 8494151 |
| 4. | FMR Inc | 2 years ago | 3847678 |
| 5. | venBio Select Advisor LLC | 2 years ago | 2580000 |
| 6. | Adage Capital Partners Gp LLC | 2 years ago | 2284913 |
| 7. | T. Rowe Price Associates, Inc. | 2 years ago | 2135883 |
| 8. | Holocene Advisors, LP | 2 years ago | 1454869 |
| 9. | Federated Hermes Inc | 2 years ago | 1099756 |
| 10. | T. Rowe Price Investment Management,Inc. | 2 years ago | 1095101 |
| 11. | Darwin Global Management, Ltd. | 2 years ago | 1039289 |
| 12. | Westfield Capital Management Company, LP | 2 years ago | 910873 |
| 13. | Polar Capital Holdings PLC | 2 years ago | 857957 |
| 14. | Fred Alger Management, LLC | 2 years ago | 666722 |
| 15. | Marshall Wace Asset Management Ltd | 2 years ago | 510946 |
| 16. | Pictet Asset Manangement SA | 2 years ago | 499841 |
| 17. | Balyasny Asset Management LLC | 2 years ago | 424695 |
| 18. | BlackRock Inc | 2 years ago | 381726 |
| 19. | Finepoint Capital LP | 2 years ago | 360916 |
| 20. | Perceptive Advisors LLC | 2 years ago | 339012 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...